Dr Reddys Share Price Extends Fall to Fifth Straight Session, Slides to Rs 1,222 Intraday

Dr Reddys share price fell for a fifth straight session on 10 July 2026, sliding to Rs 1,222 intraday before recovering to around Rs 1,246, down over 1 percent, even as the broader market rallied.

The Dr Reddys share price extended its losing streak to a fifth consecutive session on Friday, 10 July 2026, standing out starkly against a market in which nearly every sector traded in the green. The stock slid to an intraday low of Rs 1,222.00, down as much as about 3 percent from the previous close of Rs 1,261.50, before clawing back to trade around Rs 1,246, still lower by over 1 percent, with the session’s high capped at Rs 1,250.90.

The persistence of the decline is the story. Five straight losing sessions have pulled the counter steadily towards the lower half of its 52-week range of Rs 1,148.40 to Rs 1,414.90, and Friday’s weakness came while the Nifty Pharma index itself recovered from early losses to trade near flat, confirming that the pressure on the Dr Reddys share price is stock-specific rather than purely sectoral.

Click Here – Get Free Investment Predictions

Dr Reddys Share Price Snapshot: 10 July 2026

Why the Dr Reddys Share Price Keeps Falling

Three pressures have compounded over the week. The most fundamental is the fading of the Revlimid windfall: the generic version of the blockbuster cancer drug delivered outsized, high-margin revenue to Dr Reddys over recent years, and with that opportunity now normalising as competition expands, the street has been trimming earnings estimates and questioning what fills the gap. Every soft data point on new launches gets amplified through this lens.

The second is the broader US generics grind, where pricing in the base business remains competitive and the pipeline of meaningful launches takes time to monetise. The third is positioning: pharma has been a crowded defensive shelter during 2026’s bouts of volatility, and as risk appetite returned this week, funds rotated out of the sector’s most widely held names, with Dr Reddys, among the most liquid, bearing a disproportionate share of the exits.

Review Your Pharma Holdings With a SEBI Registered Investment Advisor

What the Streak Looks Like on the Charts

Five consecutive red sessions have brought the Dr Reddys share price to a technically interesting juncture, and how the Dr Reddys share price behaves around round-figure supports will shape trader positioning. The intraday low of Rs 1,222 sits within reach of the Rs 1,200 round figure, below which the 52-week low of Rs 1,148.40 becomes the market’s reference point. On the upside, the stock needs to reclaim Rs 1,262, the previous close, to break the streak, with the Rs 1,300 to Rs 1,320 zone acting as the heavier supply area where the decline began.

Notably, Friday’s recovery from the lows, alongside a still-healthy analyst score on the counter, suggests value-oriented buyers are beginning to probe. Streaks of five or more losing sessions in largecap pharma names have historically been followed by stabilisation more often than capitulation, though the catalyst usually needs to come from earnings or pipeline news rather than technicals alone.

What Should Investors Watch Next

The upcoming Q1 FY27 results are the natural circuit breaker, with the market focused on the trajectory of US revenue excluding Revlimid, the ramp of new launches including complex generics and biosimilars, margin guidance, and progress in the growth engines of India, Russia and emerging markets. Until those numbers land, the Dr Reddys share price is likely to remain hostage to flows and sector rotation, and investors should treat sharp intraday moves in either direction with corresponding scepticism.

The Revlimid Cliff: Understanding the Overhang on Dr Reddys Share Price

No single factor explains the pressure on the Dr Reddys share price better than the arithmetic of generic Revlimid. The lenalidomide opportunity, opened by settlement-defined volume limits in the US market, delivered extraordinary revenue at margins the base business cannot replicate, and it flowed almost directly to the bottom line during its peak years. As competition on the molecule broadens and pricing normalises, that contribution shrinks quarter by quarter, mechanically dragging reported growth even when the underlying business performs adequately.

The street’s anxiety is not that Dr Reddys will shrink catastrophically, but that the bridge to the next growth drivers, complex generics, biosimilars including its oncology and immunology pipeline, consumer healthcare and emerging markets, takes longer to build than the Revlimid runway takes to fade. Every quarter of the transition invites recalculation, and stocks mid-transition tend to derate first and rerate only when the new engines prove themselves in numbers.

This framing also clarifies what would end the losing streak in the Dr Reddys share price: not a broad pharma rally, but company-specific evidence, a strong biosimilar launch update, a complex generic approval, or India business acceleration, that the post-Revlimid earnings base is forming faster than feared.

The divergence within the sector sharpens the picture: on the same day the Dr Reddys share price extended its streak, thirteen other stocks hit fresh 52-week highs and pharma peers recovered from morning losses, confirming that this is a company-specific repricing. For long-term investors, such episodes are worth studying rather than fearing, since the Dr Reddys share price has historically rewarded those who bought transition-driven derating phases once the new earnings base became visible.

Download the Univest iOS App or Univest Android App to track Dr Reddys live prices, results and expert trade ideas.

Conclusion

The Dr Reddys share price fell for a fifth straight session on 10 July 2026, touching Rs 1,222 before recovering to about Rs 1,246, extending a decline rooted in the fading Revlimid opportunity, a grinding US generics market and rotation out of crowded defensive positions. With the stock now in the lower half of its 52-week band and the Q1 FY27 results approaching, the streak has set up a clear test: earnings that reassure on the post-Revlimid growth path would likely end the slide, while another soft quarter would put the Rs 1,148 low back in the conversation.

FAQs About Dr Reddys Share Price

Why is Dr Reddys share price falling for five straight sessions?

Ans. The decline reflects concerns over the fading high-margin Revlimid generic opportunity, continued pricing pressure in the US generics base business, and rotation out of crowded defensive pharma positions as broader market risk appetite returned.

How much did Dr Reddys fall on 10 July 2026?

Ans. The stock slid to an intraday low of Rs 1,222.00, down about 3 percent from the previous close of Rs 1,261.50, before recovering to trade around Rs 1,246, still lower by over 1 percent.

What is the 52-week range of Dr Reddys?

Ans. Dr Reddys has traded between a 52-week low of Rs 1,148.40 and a 52-week high of Rs 1,414.90. The current price sits in the lower half of that band.

Is the fall in Dr Reddys stock-specific or sector-wide?

Ans. Largely stock-specific. On 10 July 2026 the Nifty Pharma index recovered to trade near flat while Dr Reddys remained among the worst performers, indicating pressure concentrated in the counter.

What are the key support and resistance levels for Dr Reddys?

Ans. Support lies at Rs 1,222, the day’s low, then the Rs 1,200 round figure and the 52-week low of Rs 1,148.40. The stock needs to reclaim Rs 1,262 to end the streak, with heavier resistance at Rs 1,300 to Rs 1,320.

What should investors watch in Dr Reddys Q1 FY27 results?

Ans. Key items include US revenue trends excluding Revlimid, the ramp of new launches such as complex generics and biosimilars, margin guidance, and growth in India, Russia and emerging markets.

Does a five-session losing streak signal more downside?

Ans. Not necessarily. In liquid largecap pharma names, extended streaks have more often been followed by stabilisation, though a durable reversal typically needs an earnings or pipeline catalyst rather than technical factors alone.